9.11.20
6 min. Read

32 Pear patents. Amwell $644M IPO.

Issue 069

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about how "breakthrough" is "too breakthrough" to secure CMS reimbursement under its latest proposed rule. Plus -- continuing on the "break" theme -- I posted the numbers related to Teladongo merger break-up fees. Finally, I dug into how some think about the regulated and unregulated

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
Help me get ahead. $200/year

Prescription Digital Therapeutics

All Newsletters
    209 articles
  • First
  • Previous
    • 1 of 21
  • Next
  • Last
Mahana Therapeutics’ insolvency. FDA clears Happy Ring (Tinder founder’s smart ring)
10.04.24
6 min. Read
Flashback: How Proteus Digital Health’s outcomes-based pricing worked for Tennessee Medicaid
9.20.24
5 min. Read
Are the Digital Mental Health Treatment G Codes necessary? Or RTM dupes?
7.12.24
7 min. Read
Which PDTs are still around? New bill in Congress.
6.28.24
10 min. Read
FDA OKs Alivecor (12L?), Akili OTC. Oui eyes obesity.
6.21.24
5 min. Read
Digging into the Akili-Virtual Therapeutics deal
5.31.24
10 min. Read
CMS questions MedRhythms on InTandem
5.17.24
5 min. Read
MedRhythms-Alexion. Akili RCT for OTC.
4.26.24
6 min. Read
Hints about Otsuka’s commercialization plan for Rejoyn
4.16.24
6 min. Read
Better Therapeutics shuts down. Mahana-Cara Care
3.15.24
5 min. Read
  • First
  • Previous
    • 1 of 21
  • Next
  • Last